Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance

Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance

Abstract We reported a patient with unresectable hepatocellular carcinoma (HCC) who initially received 15 cycles of atezolizumab plus bevacizumab combination and had best tumor response of partial response, but later experienced disease progression. After subsequent surgical resection, the patient e...

Full description

Bibliographic Details
Main Authors: Yulei Wang, Li-Chun Lu, Yinghui Guan, Ming-Chih Ho, Shan Lu, Jessica Spahn, Chih-Hung Hsu
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Experimental Hematology & Oncology
Subjects:
Atezolizumab
Bevacizumab
Hepatocellular carcinoma
Immune exclusion
PD-L1
Online Access:https://doi.org/10.1186/s40164-021-00237-y

Internet

https://doi.org/10.1186/s40164-021-00237-y

Similar Items